Cash Flow Statement

Asset Writedowns and Impairment Capital Expenditures Cash from Financing Activities Cash from Investing Activities Cash from Operations Change in Account Payables Change in Accured Expenses Change in Acquisitions & Divestments Change in Cash Depreciation & Amortization (CF)Depreciation and Depletion Free Cash Flow Gains from Investment Securities Net Cash Flow Net Income Non-cash Items Sales of Property, Plant and Equipment Share-based Compensation Shares Issued

Daily Values

Others

Candel Therapeutics (CADL) Asset Writedowns and Impairment (2023)

Candel Therapeutics' Asset Writedowns and Impairment history spans 1 years, with the latest figure at $228000.0 for Q4 2023.